SCHEMBL6490073

SCHEMBL6490073

COc1cc(Nc2ncnc(-n3c(NCc4cccc([N+](=O)[O-])c4)nc4ccccc43)n2)cc(OC)c1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.64
LCK P06239 3/20 0.64
MAPK14 Q16539 2/20 0.64
PDE5A O76074 1/20 0.49
IGF1R P08069 3/20 0.47
ALK Q9UM73 1/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
PIK3CA P42336 4/20 0.43
MTOR P42345 4/20 0.43
PTK2 Q05397 2/20 0.42
PLK1 P53350 1/20 0.42
PIK3CD O00329 1/20 0.41
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
TGFBR2 P37173 1/20 0.41
PIK3CB P42338 1/20 0.41
CSNK1D P48730 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478502 0.93 KDR (0.65) KDRLCKMAPK14PDE5AIGF1R
SCHEMBL14214614 0.89 KDR (0.78) KDRLCKMAPK14IGF1RALK
SCHEMBL6492655 0.87 KDR (0.68) KDRLCKMAPK14IGF1RPIK3CA
SCHEMBL14214681 0.84 KDR (0.71) KDRLCKMAPK14PDE5AIGF1R
SCHEMBL6478783 0.84 KDR (0.70) KDRLCKMAPK14IGF1RALK
SCHEMBL14214727 0.80 KDR (0.71) KDRLCKMAPK14IGF1RPIK3CA
SCHEMBL14214680 0.77 LCK (0.76) KDRLCKMAPK14IGF1RMAPT
SCHEMBL14214730 0.77 KDR (0.82) KDRLCKMAPK14IGF1RMEN1
SCHEMBL14214616 0.77 KDR (0.84) KDRLCKMAPK14IGF1RALK
SCHEMBL14214609 0.76 KDR (0.87) KDRLCKMAPK14IGF1RALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
EP-1385833-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Amgen Inc. (US) 2004-02-04 EP disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed
WO-2002083654-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA KDR 4/4885LCK 1859/4885MAPK14 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.